Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Impedimed Limited ( (AU:IPD) ) just unveiled an announcement.
ImpediMed has issued 299,566,200 fully paid ordinary shares at $0.01 each to institutional, professional and sophisticated investors under a placement announced earlier in May, expanding its share base and raising additional capital. The company confirmed that the shares were issued without a disclosure document under the Corporations Act, while stating it remains in compliance with financial reporting and continuous disclosure requirements and that there is no excluded information requiring disclosure, providing regulatory assurance to investors.
The cleansing notice formally documents the status of the new share issuance, ensuring the new shares can be traded without further disclosure and underscoring ImpediMed’s adherence to statutory obligations. This step supports liquidity for the newly issued stock and signals to the market that the company’s governance and reporting remain in good standing, which may bolster confidence among existing and new shareholders.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.02 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited is an Australian medical technology company listed on the ASX that issues fully paid ordinary shares to institutional, professional and sophisticated investors as part of its capital management activities. The company operates under the Australian Corporations Act compliance framework and maintains adherence to continuous disclosure obligations.
Average Trading Volume: 4,804,588
Technical Sentiment Signal: Sell
Current Market Cap: A$16.31M
See more data about IPD stock on TipRanks’ Stock Analysis page.